期刊文献+

恶性肿瘤化疗后应用粒细胞集落刺激因子的疗效观察 被引量:3

下载PDF
导出
摘要 目的探讨临床肿瘤患者化疗后不同时期应用重组人粒细胞集落刺激因子(rhG-CSF)的疗效。方法选择上一周期化疗后中性粒细胞数(ANC)降至1.5×109/L以下的肿瘤患者共50例,分为A组与B组,分别在下一周期化疗结束48h后和中性粒细胞计数(ANC)<1.5×109/L时使用rhG-CSF,连续2dANC>2.0×109/L停药,观察ANC变化情况及感染的发生率。结果A组ANC持续<1.5×109/L的天数,ANC恢复至≥2.0×109/L所需的天数均小于B组(P<0.01),ANC最低值高于B组(P<0.05),用药天数较B组少(P<0.05),感染的发生率低于B组(P<0.05)。结论对恶性肿瘤患者化疗后可能发生粒细胞减少倾向的患者建议化疗结束48h后立即使用rhG-CSF。
出处 《江西医药》 CAS 2009年第11期1105-1107,共3页 Jiangxi Medical Journal
  • 相关文献

参考文献5

二级参考文献14

  • 1石远凯,周际昌,冯奉仪,曾万勇,李青,何小慧,张弘刚,张湘茹,周立强.基因重组人粒细胞集落刺激因子对肿瘤化疗所致白细胞减少的临床疗效观察[J].中华肿瘤杂志,1994,16(3):207-210. 被引量:35
  • 2石远凯,孙燕,苏嵋,李利亚,刘云英,王金万,张湘茹,崔巍.基因重组人粒细胞/巨噬细胞集落刺激因子预防化疗所致白细胞减少症的临床疗效观察[J].中华肿瘤杂志,1994,16(5):356-359. 被引量:33
  • 3沈倍奋,杨子义,许锦良,丁林茂,吕秋军,鲍云华,吴进冬,杨志刚,赖春宁,陈兴.重组人粒细胞巨噬细胞集落刺激因子的研究[J].中华医学杂志,1996,76(9):654-657. 被引量:8
  • 4Aher D, Green M, Bishop J, et al. Randomized,placebo- controlled trial of Filgrastim (r - metHuG - CSF) in patients with febrile neutropenia(FN) following chemotherapy, abstracted[ J]. Proc Am Soc Clin Oncol 1993,12:434. :,".
  • 5Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony -stimulating factor inpatients[ J]. Br J cancer , 1988,58( 1 ) :64 - 69.
  • 6Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol, 2003, 21:3357-3365.
  • 7Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet, 2005, 365:1687-1717.
  • 8Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxil but not from escalating doxorubicin does in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncol, 2003, 21:976-983.
  • 9Rodenhuis S, Richel DJ, Van der Wall E, et al. Randomized trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet, 1998, 352:515-521.
  • 10Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst, 2000, 92:225-233.

共引文献15

同被引文献31

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部